When considering the proliferative counterparts, our results suggest that the acquisition of a primed apoptotic landscape associated with an exquisite senolytic response of p16-null/p53-proficient A549 TIS cancer cells to ABT-263/navitoclax and A1331852 is the exception rather than the rule. This evidence concerns the gene TP53 and cancer.